Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study

    Diabetes Care Date published:

  • 1054-05 EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Date published:

  • EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL

    Journal of the American College of Cardiology Date published:

  • Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals

    Nephrology Dialysis Transplantation Date published:

  • Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Journal of the American Heart Association Date published:

  • Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%

    Circulation Date published:

  • DRUG INDUCED ACUTE INTERSTITIAL NEPHRITIS ASSOCIATED WITH NEPHROGENIC DIABETES INSIPIDUS

    Date published:

  • A tRial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in HemoDialysis Patients: A Safety Device Study

    Blood Purification Date published:

  • How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

    Kidney and Blood Pressure Research Date published:

  • Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

    Kidney International Date published:

  • Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?

    Nephrology Dialysis Transplantation Date published:

  • Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

    Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities

    American Journal of Kidney Diseases Date published: